Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial

Cancer Clinical Trial

— NHS-Galleri  

Official title:

A Randomized, Controlled Trial to Assess the Clinical Utility of a Multi-cancer Early Detection (MCED) Test for Population Screening in the United Kingdom (UK) When Added to Standard of Care

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05611632
• Other study ID #: GRAIL-009
• Secondary ID: ISRCTN91431511
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 31, 2021
• Est. completion date: February 28, 2026

Study information

• Verified date: October 2022
• Source: GRAIL, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers. The trial aims to see if using the Galleri test alongside standard cancer testing in the NHS can help to find cancers at an early stage when they are easier to treat. The trial has enrolled approximately 140,000 participants who will be actively followed for approximately three years from the date of enrollment.

Description:

This is a prospective, randomized, controlled trial to assess the performance and clinical utility of a multi-cancer early detection test for population screening in the UK when added to standard of care. Participants and the study teams remain blinded throughout the study with the exception of the study nurses returning the results and a small number of staff to enable them to perform administrative duties. Blinding is maintained for participants with the exception of those participants who test positive. Those who test positive will be informed by designated trial staff and will be referred for standard of care investigations and treatment. Trial sponsor employees, the CIs and site staff (unless identified differently in the blinding plan for study conduct needs) will remain blinded throughout the study. Randomization will be to either the intervention arm, with blood collection and evaluation of the test with consequent investigation and treatment of a positive test through referral to the NHS urgent two week wait pathway, or to the control arm, where blood samples are collected at designated intervals and will be stored for potential future evaluation, but participants do not receive test results and otherwise continue to receive routine NHS care. Unless diagnosed with cancer, participants in both arms will be asked to return for annual visits at approximately 12 and 24 months. All participants whether test positive, test negative or not tested will be followed for cancer and associated outcomes via NHS dataset linkages.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 140000
• Est. completion date: February 28, 2026
• Est. primary completion date: July 15, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 77 Years

Eligibility

Inclusion Criteria:

1. Participants must be at 50-77 years of age, inclusive, at the time of data extraction from NHS datasets or GP records used to identify potential participants; and

2. Capable of giving signed and legally effective informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol. Consent provided by a legally authorised representative is not permitted in this protocol.

Exclusion Criteria:

1. Previous or current participation in another GRAIL-sponsored study.

2. Personal history of invasive cancer or haematologic malignancy, diagnosed within the three years prior to expected enrolment date. Note: Individuals with a diagnosis of non-melanoma skin cancer and prostate cancer patients whose only treatment is active surveillance are NOT excluded

3. Definitive treatment for invasive cancer or haematologic malignancy within the 3 years prior to expected enrolment date, including adjuvant hormone therapy for cancer (e.g. for breast or prostate cancer).

4. Currently taking demethylating or cytotoxic agents for any condition.

5. Undergoing current investigation for suspected cancer, defined as having been referred to a two week wait clinic or undergoing investigations at an RDC or other clinic with a stated suspicion of cancer.

6. Currently on a palliative care pathway.

Related Conditions & MeSH terms

• Cancer

Intervention

Device:
• Multi-cancer early detection test (Galleri test)
Blood collection and multi cancer early detection testing with return of positive test results.

Locations

Country	Name	City	State
United Kingdom	EMS Healthcare Ltd	Chester

Sponsors (2)

Lead Sponsor	Collaborator
GRAIL, LLC	Cancer Research UK and King's College London Cancer Prevention Trials Unit (UK)

Country where clinical trial is conducted

United Kingdom, 

References & Publications (3)

Brentnall AR, Mathews C, Beare S, Ching J, Sleeth M, Sasieni P. Dynamic data-enabled stratified sampling for trial invitations with application in NHS-Galleri. Clin Trials. 2023 Apr 24:17407745231167369. doi: 10.1177/17407745231167369. Online ahead of print. — View Citation

Neal RD, Johnson P, Clarke CA, Hamilton SA, Zhang N, Kumar H, Swanton C, Sasieni P. Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial. Cancers (Basel). 2022 Oct 1;14(19):4818. doi: 10.3390/cancers14194818. — View Citation

Sasieni P, Smittenaar R, Hubbell E, Broggio J, Neal RD, Swanton C. Modelled mortality benefits of multi-cancer early detection screening in England. Br J Cancer. 2023 Apr 25. doi: 10.1038/s41416-023-02243-9. Online ahead of print. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	healthcare resource utilisation	The data collected may be used to conduct future exploratory economic analyses, and will include: Number and types of medical encounters and cancer-specific diagnostic and treatment procedures, including clinical lab visits, imaging tests, invasive tests, and clinic visits.	Up to 3 years
Primary	absolute numbers of stage III and IV cancers diagnosed		3-4 years after randomization
Secondary	absolute numbers of advanced cancers (stage III and IV cancers or one that results in a cancer-specific death) diagnosed		3-4 years after randomization
Secondary	absolute numbers of stage IV cancers diagnosed		1 years after randomization
Secondary	absolute numbers of stage IV cancers diagnosed		3-4 years after randomization
Secondary	cancer-specific mortality for a pre-specified group of cancer types		3-4 years after randomization
Secondary	cancer-specific mortality		up to 8 years after randomization
Secondary	proportion of Stage I and II cancers		3-4 years after randomization
Secondary	test performance (sensitivity, specificity, positive predictive value, negative predictive value) and cancer signal origin accuracy) in the intervention arm.		Up to 3 years
Secondary	number of follow up procedures and invasive procedures, complications and deaths associated with follow-up diagnostic procedures in all test positive cases		Up to 3 years
Secondary	number and type of invasive procedures performed in false positive cases		Up to 3 years
Secondary	radiation exposure measured in mSv per participant due to test result directed evaluations in all test positive cases		Up to 3 years
Secondary	psychological impact using the short form State Trait Anxiety Index-6 questionnaire (a six item validated measure of state anxiety), at various timepoints in all test positive cases	Scores range from 20-80 with the general population expected to score 34-36 and very high anxiety classed as scoring > 49.	Up to 3 years